BioSig Engages FDA Consulting Firm for 510(k) Approval & QA Advisory; Company Taps CRO Industry Leader Libra Medical
ACCESSWIRE - Mon Dec 01, 8:00AM CST
LOS ANGELES, CA / ACCESSWIRE / December 1, 2014 / BioSig Technologies (OTCQB: BSGM), a medical device company that has developed and is preparing to commercialize its proprietary PURE EP(TM) technology platform designed to greatly improve the clinical value of electrophysiological (EP) cardiac recordings, today announced it has retained Libra Medical, Inc. for Regulatory Affairs and Quality Assurance services in support of the Company's planned 510(k) application to the FDA for its PURE EP System.
BioSig Technologies, Inc. (OTCQB: BSGM), Which is Going Commercial to Improve Recording Signals Used to Treat Abnormal Heartbeats, is Featured in Flaherty Special Situation Newsletter
ACCESSWIRE - Tue Nov 25, 7:16AM CST
WEST HARRISON, NY / ACCESSWIRE / November 25, 2014 / The race for BioSig Technologies, Inc. (OTCQB: BSGM) to record abnormal heartbeat wave signals and significantly improve innovation-starved arrhythmia treatment is described in the November 20, 2014 issue of Flaherty Special Situation Newsletter. (Also in this issue is our Follow Up: Remembering the fairy tale life of one of America's first female financial writers, courageous Clare Reckert of The New York Times.)
BioSig to Present at LD Micro Main Event Conference Dec. 4
ACCESSWIRE - Mon Nov 24, 12:34PM CST
LOS ANGELES, CA / ACCESSWIRE / November 24, 2014 / BioSig Technologies (OTCQB: BSGM), a medical device company that has developed and is preparing to commercialize its proprietary PURE EP(TM) technology platform designed to greatly improve the clinical value of cardiac recordings in the $3 billion electrophysiology (EP) marketplace, today announced that its President and CEO Gregory D. Cash will present at the 7th Annual LD Micro Main Event Conference on Thursday, December 4, 2014 at 12:00 p.m. Pacific. The Conference is being held at the Luxe Sunset Bel Air Hotel in Los Angeles, California (www.ldmicro.com).
BioSig Engages Financial Profiles for Investor Relations
ACCESSWIRE - Mon Nov 17, 8:00AM CST
LOS ANGELES / ACCESSWIRE / November 17, 2014 / BioSig Technologies (OTCQB: BSGM), a medical device company that has developed and is preparing to commercialize its proprietary PURE EP(TM) technology platform designed to greatly improve the clinical value of cardiac recordings in the $3 billion electrophysiology (EP) marketplace(1), today announced it has retained Financial Profiles, Inc. as its investor relations firm.
BioSig Issues Special Letter to Shareholders
ACCESSWIRE - Mon Nov 10, 7:02AM CST
Los Angeles, CA / ACCESSWIRE / November 10, 2014 / BioSig Technologies, Inc. (OTCQB: BSGM) today issued the following Special Letter to Shareholders from its Chief Executive Officer, Gregory D. Cash.
BioSig Begins Trading with Ticker Symbol BSGM
ACCESSWIRE - Thu Nov 06, 3:00PM CST
Los Angeles, CA / ACCESSWIRE / November 6, 2014 / BioSig Technologies (OTCQB: BSGM), a company that has developed and is preparing to commercialize its proprietary PURE EP(TM) technology platform designed to greatly improve the clinical value of cardiac recordings in the $3 billion electrophysiology (EP) marketplace(1), today announced it has received notice from the Depository Trust Company (DTC) that its common stock is now fully DTC eligible for trading.